Chapter 22 Flashcards

1
Q

normal hemostasis

A

Blood usually fluid

Seals broken blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

abnormal hemostasis

A

Inappropriate clotting: too much

Insufficient clotting: too little

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

hemostasis

A

stopping blood flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

mediators of hemostasis

A

chemicals produced by platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

mediators of hemostasis is released at an injury to

A
Start clotting by reacting with blood proteins
Help platelets stick together 
Stimulate wound healing
Help platelets stick to vessel wall
Constrict blood vessels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

requirements for blood clotting process

A

Presence of platelets produced in the bone
marrow
Von Willebrand factor generated by the
vessel endothelium
Clotting factors synthesized in the liver
using vitamin K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

stages of hemostasis

A
  1. vessel spasm
  2. platelet plug formation
  3. blood coagulation
  4. fibrin clot
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

vessel spasm

A
Constriction
– Endothelial Injury initiates
– Vascular spasm/ Vascular Vasoconstriction of the smooth muscle in the vessel wall
• decreased Blood Flow
– Short Lived and Localized
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

platelet plug formation

A

– Release of von Willebrand’s Factor
• By Endothelial Cells & Platelets
- adhesion of platelets to exposed collagen fibers
– platelets become activated and secrete Adenosine diphosphate (ADP) (Promotes Aggregation), then attract more platelets
– Result: Platelet Plug (not a clot)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

blood coagulation

A
Two ways to get there
• Extrinsic Pathway
• Intrinsic Pathway
• Ultimately Both end in X Factor to activate 
Factor Xa - (Common Pathway)
– Prothrombin to Thrombin 
– Fibrinogen to fibrin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

without thrombin, what cannot occur?

A

aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

extrinsic pathway

A
  • occurs in the tissues (outside the vessel)
  • clotting process to take a chemical shortcut
  • takes 10-15 secs, measured by value PT
    production of thrombin is low, clot is small
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

intrinsic pathway

A
  • collagen in blood vessel wall activates
  • 5-10 minuets but measured as a PTT lab value
  • larger amounts of thrombin, large clot
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Factor X (active)

A

Prothrombin Activator

without it - Cannot clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Factor V Complex

A

Prothrombin to Thrombin

without it - cannot clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

conversion of Thrombin (enzyme)

A

accelerates the
formation of Fibrin threads from Fibrinogen
(Factor I) that creates insoluble blood clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

common pathway of hemostasis

A

factor X (active) -> factor V complex + calcium -> conversion of prothrombin to thrombin -> converts fibrinogen to fibrin-> fibrin clot; both extrinsic and intrinsic pathways will end up in the common pathway.

18
Q

clot retraction and dissolution

A

retraction- actin and myosin contract, pull out the fibrin, serum is squeezed out of the clot, clot shrinks
dissolution- Enzyme Plasmin Digests Clot

19
Q

alterations of coagulation

A

vitamin K deficiency, liver disease

20
Q

vitamin K

A

Vitamin K is necessary for synthesis and
regulation of components that make a clot
(stored in liver) fat-soluble vitamin (no vitamin K-> you will bleed/ inability to clot)

21
Q

liver disease

A

– Causes a broad range of hemostasis disorders -
– Many Coagulation factors made or stored in
liver
– Causes defects in coagulation, fibrinolysis, and
platelet number and function
- ppl w liver disease are very prone to bleeding bc their liver does not make the clotting factors

22
Q

Thrombocytopenia

A

platelet count <150,000/mm^3

  • <50,000- hemorrhage from minor trauma
  • <15,000- spontaneous bleeding
  • <10,000- severe bleeding
23
Q

causes of Thrombocytopenia

A

Hypersplenism, autoimmune disease,
hypothermia, and viral or bacterial infections
that cause DIC (disseminated intravascular
coagulation)

24
Q

platelets

A
live 8–10 days in circulation
– Many are stored in the spleen
– Released when needed
– Normal Value 150,000 - 400,000 *need to know this 
– Disc-shaped essential for clotting
25
Q

Hypercoagulability

A

states are either inherited or acquired
increased platelet function - increase in number, increase in procoagulation and decrease in anticoagulation during an endothelial injury

26
Q

Inherited hypercoagulation

A

Usually associated with venous thrombosis;
Deficiency of Protein C or S
factor V Leiden

27
Q

protein C and S

A

work together to
inactivate factors Va(cause clot) and
VIIIa(causes clot) (in order to stop the
clot) So if there is not enough C or S clots
are more probable

28
Q

protein C deficiency

A

common DVT

29
Q

Protein S deficiency

A

risk of ARTERIAL

thrombosis

30
Q

Factor V Leiden (FVL) (Deficiency)

A
AKA Activated protein C resistance = 
Clotting
–Genetic mutation of factor V which 
causes resistance to the action of 
Protein C (Unable to stop the 
CLOT!; C would normally stop clot 
from Continuing)
31
Q

most common acquired increase in clotting

A
- Smoking
– Disseminated Cancer
– Diabetes
– Obesity
– Can also be related to other Diseases
• Polycythemia Vera (too many RBC)
• Sickle Cell Disease
Most common Female Acquired 
– Use of Oral Contraceptives
32
Q
Hypercoagulability due to increased platelet 
function results in
A

platelet adhesion,
formation of platelet clots, and disruption of
blood flow.

33
Q

causes of increased platelet function

A

disturbances in flow, endothelial
damage, and increased sensitivity of
platelets to factors that cause adhesiveness
and aggregation.

34
Q

thrombocytopenia

A

Results from a decrease in platelet production,
increased sequestration of platelets in the
spleen, or decreased platelet survival
can be due drugs (chemo, heparin), idiopathic (cant be identified), immune system/infections, radiation therapy, autoimmune

35
Q

Von Willebrand Disease

A
  • Defect in vWF (does not allow platelets to aggregate)
    – Normal platelet Count with prolonged bleeding
    – Affects men and women
    – Multiple variants (3 variations)
36
Q

hemophilia

A

 Most common X-linked genetic disease
 Female cases rare
 Lack of Clotting Factors prevents stable clot
 Hemophilia A >80% of all hemophiliacs (aka
classic, Factor VIII or A)
 Hemophilia B aka Christmas Disease (Factor IX)

37
Q
Disseminated 
Intravascular Coagulation (DIC)
A

 Complex, acquired disorder: clotting and
hemorrhage simultaneously occur
– Sepsis, cancer, trauma, blood transfusion, shock
 Endothelial damage or Tissue Damage is
primary initiator
 Results in Clotting that leads to Bleeding

38
Q

anticoagulant drugs

A

Heparin
• binds to AT to produce an anticoagulant effect
– Coumadin drugs interfere with vitamin K action of the liver
(oral)

39
Q

antiplatelet drugs

A

(inhibits platelet plug formation)
– Aspirin
• Decrease platelet adherence and may increase bleeding
• Clopidogrel (Plavix) - Prevention of platelet
aggregation
 Thrombolytic Drugs
– Plasminogen activators are used to lyse thrombi in vivo

40
Q

antithrombotic therapy - aspirin

A

– Administration results in irreversible inhibition
of the platelet enzyme cyclooxygenase, which is
needed for proper platelet aggregation
– This reduces the “stickiness” of platelets
– Affects last for the lifetime of the platelets – 7-10
days
– NSAID drugs such as ibuprofen compete for
cycloxygenase and may be used in conjunction
with aspirin

41
Q

Plavix (clopidogrel)

A

a specific
inhibitor of ADP-induced platelet
aggregation